NCT04718467撤回2 期
A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱb Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 to 85 Years Old
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- The incidence of adverse reaction (AR)
研究概览
简要总结
This is a phase Ⅱb, single-center, randomized, double-blind, placebo-controlled study, to evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (Sf9 cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-59 and 60-85 years) with immunization procedures 0, 21, 42 days and doses 40μg.
详细描述
This is a phase Ⅱb, single-center, randomized, double-blind, placebo-controlled study, to evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (Sf9 cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-59 and 60-85 years) . The phase Ⅱb clinical trials designed two research group, including adults group (aged 18-59 years) and elderly adults group (aged 60-85 years). Each group including 2000 participants. Vaccination or placebo group will be randomly assigned to receive in a 3:1 ratio, 4000 in total.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 18-85 years old
- •Able to understand the content of informed consent and willing to sign the informed consent.
- •Able and willing to complete all the secluded study process during the whole study follow-up period (about 14 months).
- •Axillary temperature ≤37.0℃
排除标准
- •Positive serum immunoglobulin M (IgM) and immunoglobulin G (IgG) to the SARS-CoV-
- •SARS-CoV-2 nucleic acid testing positive.
- •History of SARS-CoV-2 infection or vaccination
- •A Known History of HIV infection
- •Family history of seizure, epilepsy, brain or mental disease.
- •Participant that has an allergic history to any ingredient of vaccines.
- •Woman who is pregnant, breast-feeding or positive in pregnancy test on day of enrollment, or is planning to be pregnant during the next 14 months.
- •Any acute fever disease or infections.
- •Have a medical history of SARS.
- •Have serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and not well-controlled.
- •Major chronic illness, such as asthma, diabetes, or thyroid disease, and not well-controlled.
- •Malignant tumor, activity or have been treated tumor and no clear have cured, or during the study period is likely to relapse.
- •Hereditary angioneurotic edema or acquired angioneurotic edema.
- •Urticaria in last one year.
- •Asplenia or functional asplenia.
- •Platelet disorder or other bleeding disorder may cause injection contraindication.
- •Faint at the sight of blood or needles.
- •Prior administration of immunodepressant or corticosteroids, antianaphylactics treatment, cytotoxic treatment in last 6 months.
- •Prior administration of blood products in last 4 months.
- •Prior administration of other research medicines in last 1 month.
- •Prior administration of attenuated vaccine in last 1 month.
- •Prior administration of subunit vaccine or inactivated vaccine in last 14 days.
- •Nearly 7 days, all sorts of acute onset of disease or chronic diseases, such as receiving anti-tuberculosis treatment, history of asthma.
- •According to the investigator's judgment, due to various medical, psychological, social or other conditions, it is contrary to the trial protocol or affects the subjects to sign informed consent.
- •Exclusion criteria for subsequent doses:
- •Appear systemic allergic reaction, severe allergic reactions.
- •Appear difficult to tolerate more than grade 3 adverse reactions.
- •New discovery or a new happened after the first vaccination does not conform to the first dose of the inclusion criteria or conform to the first dose of exclusion criteria, determine whether or not to continue to participate in the study by the investigators.
- •Investigators think of other reasons.
结局指标
主要结局
The incidence of adverse reaction (AR)
时间窗: 0 to 7 days after each dose
The incidence of adverse reaction (AR)
The incidence of Adverse Events of Special Interest (AESI)
时间窗: from day 0 to day 60 after last dose
The incidence of Adverse Events of Special Interest (AESI)
次要结局
- The incidence of adverse events (AE)(from day 0 to day 30 after last dose)
- The incidence of severe adverse events (SAE)(Month 12 after the whole process of vaccination)
- Geometric mean (GMT) of specific antibody(day 30, day 60, month 6, month 12 after last dose)
- The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody(day 30, day 60, month 6, month 12 after last dose)
- Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies(day 30, day 60, month 6, month 12 after last dose)
- The incidence of grade 3 adverse events (AE)(from day 0 to day 30 after last dose)
- Geometric mean fold increase (GMI) of S-RBD protein-specific antibody(day 30, day 60, month 6, month 12 after last dose)
- The positive conversion rate of S-RBD protein-specific antibody(day 30, day 60, month 6, month 12 after last dose)
- Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies(day 30, day 60, month 6, month 12 after last dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)COVID-19NCT04640402Jiangsu Province Centers for Disease Control and Prevention960
进行中（未招募）
2 期
HRS9531 Controls Weight Regain in Obese SubjectsObesityNCT06287437Shanghai Zhongshan Hospital72
已完成
2 期
Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)Idiopathic Pulmonary FibrosisNCT05621252Pliant Therapeutics, Inc.10
撤回
2 期
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine ScarsUterine ScarNCT02968459Maternal and Child Health Hospital of Foshan
已完成
2 期
Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)NCT03938246Sagimet Biosciences Inc.142